Lv11
10 积分 2024-03-15 加入
A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
1小时前
待确认
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer
1小时前
已完结
A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
1小时前
已完结
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer
1小时前
已完结
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study
11天前
已完结
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
11天前
已完结
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
23天前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
23天前
已完结
MET alterations in advanced non-small cell lung cancer
25天前
已完结
MET alterations in NSCLC—Current Perspectives and Future Challenges
30天前
已完结
皖公网安备34019202002308
